@article{RoyLachanceCohenetal.2019,
  author    = {Roy, Denis Claude and Lachance, Sylvie and Cohen, Sandra and Delisle, Jean-S{\´e}bastien and Kiss, Thomas and Sauvageau, Guy and Busque, Lambert and Ahmad, Imran and Bernard, Lea and Bambace, Nadia and Boum{\´e}dine, Radia S. and Guertin, Marie-Claude and Rezvani, Katayoun and Mielke, Stephan and Perreault, Claude and Roy, Jean},
  title     = {Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis},
  series = {British Journal of Haematology},
  volume    = {186},
  journal   = {British Journal of Haematology},
  number    = {5},
  doi       = {10.1111/bjh.15970},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227075},
  pages     = {754-766},
  year      = {2019},
  abstract  = {Graft-versus-host disease (GVHD) is a major cause of transplant-related mortality (TRM) after allogeneic haematopoietic stem cell transplantation (HSCT) and presents a challenge in haploidentical HSCT. GVHD may be prevented by ex vivo graft T-cell depletion or in vivo depletion of proliferating lymphocytes. However, both approaches pose significant risks, particularly infections and relapse, compromising survival. A photodepletion strategy to eliminate alloreactive T cells from mismatched donor lymphocyte infusions (enabling administration without immunosuppression), was used to develop ATIR101, an adjunctive therapy for use after haploidentical HSCT. In this phase I dose-finding study, 19 adults (median age: 54 years) with high-risk haematological malignancies were treated with T-cell-depleted human leucocyte antigen-haploidentical myeloablative HSCT followed by ATIR101 at doses of 1 x 10(4)-5 x 10(6) CD3(+) cells/kg (median 31 days post-transplant). No patient received post-transplant immunosuppression or developed grade III/IV acute GVHD, demonstrating the feasibility of ATIR101 infusion for evaluation in two subsequent phase 2 studies. Additionally, we report long-term follow -up of patients treated with ATIR101 in this study. At 1 year, all 9 patients receiving doses of 0 center dot 3-2 x 10(6) CD3(+) cells/kg ATIR101 remained free of serious infections and after more than 8 years, TRM was 0\%, relapse-related mortality was 33\% and overall survival was 67\% in these patients.},
  language  = {en}
}
@article{LuberLutzAbeleHornetal.2019,
  author    = {Luber, Verena and Lutz, Mathias and Abele-Horn, Marianne and Einsele, Hermann and Grigoleit, G{\"o}tz Ulrich and Mielke, Stephan},
  title     = {Excretion of Ascaris lumbricoides following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole},
  series = {Transplant Infectious Disease},
  volume    = {22},
  journal   = {Transplant Infectious Disease},
  number    = {1},
  issn      = {1399-3062},
  doi       = {10.1111/tid.13224},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-219608},
  pages     = {1-4},
  year      = {2019},
  abstract  = {Here, we present the unique case of a 51-year-old German patient with multiple myeloma excreting Ascaris lumbricoides in his stool five weeks after allogeneic hematopoietic stem cell transplantation. Stool analysis remained negative for the presence of eggs, and there was no eosinophilia in the peripheral blood at any time around stem cell transplantation. The patient was commenced on a three-day treatment with mebendazole, which was well tolerated. No serious interactions with the concomitant post-transplant medication or negative effects on the hematopoiesis were observed, and the myeloma still is in complete remission. To our knowledge, this is the first report on excretion of A lumbricoides in the context of allogeneic stem cell transplantation. The case is remarkable with view to the fact that the parasite has supposedly survived all courses of myeloma treatment including autologous and allogeneic conditioning. Parasitosis with A lumbricoides has a worldwide prevalence of about a billion and is extremely rare in northern Europe. Possibly the patient got infected during a trip to Egypt years before multiple myeloma was diagnosed.},
  language  = {en}
}